UCART123
Phase 1Withdrawn 2 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukaemia
Conditions
Acute Myeloid Leukaemia
Trial Timeline
Jul 11, 2019 → Dec 5, 2019
NCT ID
NCT04106076About UCART123
UCART123 is a phase 1 stage product being developed by Cellectis for Acute Myeloid Leukaemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04106076. Target conditions include Acute Myeloid Leukaemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukaemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04106076 | Phase 1 | Withdrawn |
| NCT03203369 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukaemia